The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) by 13 companies/universities/institutes. The top development phase for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) is phase i with five drugs in that stage. The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market are: GSK, Bio-Thera Solutions and Chongqing Precision Biotech.

The key targets in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market include Interleukin 5 (Eosinophil Differentiation Factor or B Cell Differentiation Factor I or T Cell Replacing Factor or IL5), Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).

The key mechanisms of action in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline product include Interleukin 5 (Eosinophil Differentiation Factor or B Cell Differentiation Factor I or T Cell Replacing Factor or IL5) Inhibitor with five drugs in Phase III. The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products include four routes of administration with the top ROA being Subcutaneous and six key molecule types in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market including Monoclonal Antibody, and Recombinant Enzyme.

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) overview

Wegener polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factors include age. Treatment includes immunosuppressants and corticosteroids.

For a complete picture of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.